Effect of metformin on pancreatic neuroendocrine tumors of multiple endocrine neoplasia type 1
Journal of Neuroendocrinology · 2026-04 · 38 (4)
DOI: 10.1111/jne.70166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 25.03.2026. Verfasst von Serguei V Kozlov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Preclinical Research, Frederick National Lab for Cancer Research, Center for Cancer Research, National Cancer Institute, Frederic…. Hauptthemen laut MEDLINE: Metformin, Multiple Endocrine Neoplasia Type 1, Pancreatic Neoplasms, Neuroendocrine Tumors. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Metformin is a widely prescribed medication in the management of type 2 diabetes mellitus, and numerous epidemiological studies have indicated an association between metformin use and a reduced risk of certain cancers in diabetic populations. However, evidence supporting a role for metformin in cancer prevention remains inconclusive. Exploring tumor‐preventive strategies may be particularly relevant for inherited cancer syndromes with high tumor penetrance such as pancreatic neuroendocrine tumors (PNETs) associated with multiple endocrine neoplasia type 1 (MEN1). MEN1 is caused by germline pathogenic variants in the tumor suppressor gene MEN1 , and mouse models with Men1 gene loss also develop PNETs. To evaluate whether metformin is associated with altered PNET outcomes in MEN1, we performed a retrospective analysis of MEN1 patients with PNETs, incorporating detailed clinical exposure data and complemented this analysis with a preclinical study using pancreatic islet β‐cell‐specific Men1 ‐knockout mice treated with metformin. In the clinical cohort, metformin exposure varied substantially with respect to timing and duration relative to PNET diagnosis. No statistically significant association between metformin use and overall survival or metastatic disease was detected in this limited cohort. In the mouse model, treatment with 2 mg/mL metformin in drinking water initiated post‐weaning did not prevent PNET development, nor did it alter circulating insulin or glucose levels. These findings indicate that, under the dosing and exposure conditions examined, metformin was not associated with measurable tumor‐protective or tumor‐preventive effects in MEN1‐related PNETs. The study highlights important methodological considerations, including exposure timing and statistical power, and supports the need for prospective studies initiating metformin prior to tumor development in genetically predisposed populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Advanced Preclinical Research, Frederick National Lab for Cancer Research, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
- Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Sunita K Agarwal, Smita Jha
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Cancer Institute
Zitieren
APA
Kozlov, S. V., Agarwal, S. K., Guerin, T. M., Lawrence, W. C., Bassel, L. L., Graf, A., Jha, S., Weinstein, L. S., Blau, J. E., & Del Rivero, J. (2026). Effect of metformin on pancreatic neuroendocrine tumors of multiple endocrine neoplasia type 1. Journal of Neuroendocrinology, 38(4). https://doi.org/10.1111/jne.70166
Vancouver
Kozlov SV, Agarwal SK, Guerin TM, Lawrence WC, Bassel LL, Graf A, et al. Effect of metformin on pancreatic neuroendocrine tumors of multiple endocrine neoplasia type 1. Journal of Neuroendocrinology. 2026;38(4). doi:10.1111/jne.70166
BibTeX
@article{Kozlov2026,
author = {Kozlov, Serguei V and Agarwal, Sunita K and Guerin, Theresa M and Lawrence, Wendi Custer and Bassel, Laura L and Graf, Akua and Jha, Smita and Weinstein, Lee S and Blau, Jenny E and Del Rivero, Jaydira},
title = {Effect of metformin on pancreatic neuroendocrine tumors of multiple endocrine neoplasia type 1},
journal = {Journal of Neuroendocrinology},
year = {2026},
volume = {38},
number = {4},
doi = {10.1111/jne.70166}
}
EUVIMED